MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Затворен

СекторЗдравеопазване

23.28 -2.59

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.16

Максимум

23.48

Ключови измерители
By Trading Economics
Приходи	51M -129M
Продажби	207M
Марж на печалбата	-62.319
Служители	1,371
EBITDA	8.8M -105M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+122.4% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	269M 2.2B
Предишно отваряне	25.87
Предишно затваряне	23.28

Настроения в новините

By Acuity

73%

27%

320 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

32.76 / 39.24 Подкрепа & съпротива

Ultragenyx Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 17:04 ч. UTC

Значими двигатели на пазара

FDA Rejects Replimune's Melanoma Drug for a Second Time

11.04.2026 г., 09:30 ч. UTC

Печалби

After the Great EV Slowdown, High Gas Prices Are Tempting Americans Back -- WSJ

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.04.2026 г., 00:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Big Yachts, Big Bucks -- Barrons.com

10.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10.04.2026 г., 21:01 ч. UTC

Печалби

Cango Inc.: Files Annual Report on Form 20-F With SEC

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

10.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 20:31 ч. UTC

Пазарно говорене

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10.04.2026 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

10.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

10.04.2026 г., 19:08 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

10.04.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10.04.2026 г., 18:25 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Finish With Weekly Gains -- Market Talk

10.04.2026 г., 18:05 ч. UTC

Пазарно говорене

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10.04.2026 г., 17:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10.04.2026 г., 17:26 ч. UTC

Печалби

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10.04.2026 г., 17:10 ч. UTC

Пазарно говорене

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10.04.2026 г., 17:00 ч. UTC

Значими събития в новините

Construction Business Taking a Hit From Iran Conflict -- WSJ

10.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

10.04.2026 г., 16:12 ч. UTC

Печалби

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10.04.2026 г., 16:11 ч. UTC

Печалби

Partners Group: Traditional Programs Contributed $3.3B

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10.04.2026 г., 16:10 ч. UTC

Печалби

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

Сравнение с други в отрасъла

Ценова промяна

Ultragenyx Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

122.4% нагоре

12-месечна прогноза

Среден 51.82 USD 122.4%

Висок 84 USD

Нисък 25 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Ultragenyx Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

Купи

Задържане

Продай

Според 19 анализатори, дали борсови рейтинги на Ultragenyx Pharmaceutical Inc през последните 3 месеца.

Техническа оценка

By Trading Central

32.76 / 39.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

320 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.